154 related articles for article (PubMed ID: 36058469)
1. Several non-salt and solid thienopyridine derivatives as oral P2Y
Liu L; Li L; Yuan J; Liu W; Li Y; Zhang S; Huang C
Bioorg Med Chem Lett; 2022 Nov; 75():128969. PubMed ID: 36058469
[TBL] [Abstract][Full Text] [Related]
2. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X
Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793
[TBL] [Abstract][Full Text] [Related]
3. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
Judge HM; Buckland RJ; Jakubowski JA; Storey RF
Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic basis of the antiplatelet action of prasugrel.
Schrör K; Siller-Matula JM; Huber K
Fundam Clin Pharmacol; 2012 Feb; 26(1):39-46. PubMed ID: 21895761
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
[TBL] [Abstract][Full Text] [Related]
7. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Floyd CN; Passacquale G; Ferro A
Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
[TBL] [Abstract][Full Text] [Related]
9. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
Ancrenaz V; Daali Y; Fontana P; Besson M; Samer C; Dayer P; Desmeules J
Curr Drug Metab; 2010 Oct; 11(8):667-77. PubMed ID: 20942779
[TBL] [Abstract][Full Text] [Related]
10. State of the art of new P2Y12 antagonists.
Cattaneo M; Podda GM
Intern Emerg Med; 2010 Oct; 5(5):385-91. PubMed ID: 20177818
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Máchal J; Hlinomaz O
Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
[TBL] [Abstract][Full Text] [Related]
12. [Prasugrel, a new thienopyridine].
Schrör K; Huber K
Hamostaseologie; 2007 Dec; 27(5):351-5. PubMed ID: 18060245
[TBL] [Abstract][Full Text] [Related]
13. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
14. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
Small DS; Farid NA; Payne CD; Konkoy CS; Jakubowski JA; Winters KJ; Salazar DE
Clin Pharmacokinet; 2010 Dec; 49(12):777-98. PubMed ID: 21053990
[TBL] [Abstract][Full Text] [Related]
15. Prasugrel metabolites inhibit neutrophil functions.
Liverani E; Rico MC; Garcia AE; Kilpatrick LE; Kunapuli SP
J Pharmacol Exp Ther; 2013 Jan; 344(1):231-43. PubMed ID: 23097214
[TBL] [Abstract][Full Text] [Related]
16. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
Ueno T; Koiwaya H; Sasaki KI; Katsuki Y; Katsuda Y; Murasato Y; Shimamatsu J; Umeji K; Otsuka Y; Kawasaki T; Shibata Y; Fukumoto Y
Cardiovasc Interv Ther; 2017 Oct; 32(4):341-350. PubMed ID: 27488859
[TBL] [Abstract][Full Text] [Related]
17. Study on antiplatelet effect of a new thiophenopyridine platelets P2Y
Xu Z; Gu J; Gao M; Du N; Liu P; Xu X; Wang J; Cao X
Thromb Res; 2018 Oct; 170():192-199. PubMed ID: 30199785
[TBL] [Abstract][Full Text] [Related]
18. Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options.
Trenk D; Hille L; Leggewie S; Stratz C; Nührenberg TG; Aradi D; Schrör K; Sibbing D
Thromb Haemost; 2019 Oct; 119(10):1606-1616. PubMed ID: 31408901
[TBL] [Abstract][Full Text] [Related]
19. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites.
Marsousi N; Daali Y; Fontana P; Reny JL; Ancrenaz-Sirot V; Calmy A; Rudaz S; Desmeules JA; Samer CF
Clin Pharmacokinet; 2018 Oct; 57(10):1347-1354. PubMed ID: 29453687
[TBL] [Abstract][Full Text] [Related]
20. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
